Otsuka scores PhIII win for another Astex drug; GSK expands Nucala use in asthma
→ Otsuka has some good news to report on the other drug that it obtained in the $886 million acquisition of Astex Pharmaceuticals. ASTX727 combines the chemotherapy decitabine with cedazuridine, an oral inhibitor of cytidine deaminase. A Phase III study evaluating the combo and intermediate to high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia met its primary endpoint, the company said.
→ GlaxoSmithKline has notched additional approvals for two at-home administration methods of Nucala, a win that it hopes would give it an edge in the competitive asthma market.